Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma

Figure 4 Kaplan-Meier survival estimates of progression-free survival. A: Comparison of patients with relative enhancement ratio < 0.9 and relative enhancement ratio ≥ 0.9; B: Comparison of patients with neutrophil-to-lymphocyte ratio < 5 and neutrophil-to-lymphocyte ratio ≥ 5; C: Comparison of patients with platelet-to-lymphocyte ratio < 300 and platelet-to-lymphocyte ratio ≥ 300; D: Comparison of patients with prognostic nutritional index < 45 and prognostic nutritional index ≥ 45. RER: Relative enhancement ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic nutritional index.